{{ variable.name }} : {{ variable.values[selectedVariantsIndex[variable_index]].name }}
Quantity:
Cagrilintide 5mg + Semaglutide 5mg refers to a co-formulated or combined product containing cagrilintide (a long-acting amylin receptor and calcitonin receptor agonist) and semaglutide (a glucagon-like peptide-1 [GLP-1] receptor agonist).
This combination is widely known in clinical research as CagriSema.
What is CagriSema?
• Dual Mechanism: Semaglutide stimulates GLP-1 receptors to enhance insulin secretion, suppress glucagon, and reduce appetite, while cagrilintide acts on amylin and calcitonin receptors in the brain and delays gastric emptying to promote early fullness and curb cravings.
• Clinical Studies: It has been evaluated in large-scale Phase 3 clinical trials (such as the REDEFINE program) for chronic weight management and type 2 diabetes. Results show that the combination yields significantly greater reductions in body weight and improvements in metabolic markers compared to either monotherapy alone.
• Safety & Side Effects: In clinical studies, the most common side effects of the combination are gastrointestinal (such as nausea, vomiting, or constipation), similar to other GLP-1 and amylin-based therapies